CRIS Current Research Information System

CASADEI, BEATRICE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.974
EU - Europa 6.250
NA - Nord America 4.951
AF - Africa 335
SA - Sud America 333
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 1
Totale 18.863
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.868
NL - Olanda 2.195
VN - Vietnam 1.862
SG - Singapore 1.803
CN - Cina 1.641
IT - Italia 1.158
DE - Germania 848
HK - Hong Kong 670
GB - Regno Unito 497
SE - Svezia 486
IN - India 275
BR - Brasile 238
FR - Francia 228
KR - Corea 221
RU - Federazione Russa 205
IE - Irlanda 133
FI - Finlandia 121
JP - Giappone 114
CI - Costa d'Avorio 109
UA - Ucraina 83
ZA - Sudafrica 69
TG - Togo 54
AR - Argentina 49
TH - Thailandia 49
PH - Filippine 46
ID - Indonesia 45
PL - Polonia 45
AT - Austria 43
CA - Canada 42
JO - Giordania 42
SC - Seychelles 41
BD - Bangladesh 32
ES - Italia 31
EE - Estonia 30
TR - Turchia 30
IQ - Iraq 29
NG - Nigeria 29
CH - Svizzera 27
MX - Messico 26
BE - Belgio 24
BG - Bulgaria 23
TW - Taiwan 23
AU - Australia 17
PK - Pakistan 16
SA - Arabia Saudita 15
LT - Lituania 14
CL - Cile 13
EG - Egitto 9
MY - Malesia 9
RO - Romania 9
EC - Ecuador 8
UZ - Uzbekistan 8
IR - Iran 7
PE - Perù 7
RS - Serbia 7
CZ - Repubblica Ceca 6
KE - Kenya 6
DK - Danimarca 5
GR - Grecia 5
IL - Israele 5
LB - Libano 5
PY - Paraguay 5
VE - Venezuela 5
BY - Bielorussia 4
DO - Repubblica Dominicana 4
HR - Croazia 4
MK - Macedonia 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
CG - Congo 3
MA - Marocco 3
MM - Myanmar 3
OM - Oman 3
PS - Palestinian Territory 3
PT - Portogallo 3
TT - Trinidad e Tobago 3
AL - Albania 2
AZ - Azerbaigian 2
CO - Colombia 2
DZ - Algeria 2
GE - Georgia 2
GH - Ghana 2
HU - Ungheria 2
JM - Giamaica 2
LV - Lettonia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
UY - Uruguay 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BH - Bahrain 1
BW - Botswana 1
CR - Costa Rica 1
ET - Etiopia 1
EU - Europa 1
GM - Gambi 1
GT - Guatemala 1
Totale 18.847
Salva come PNG Salva come JPEG
Città #
Singapore 1.303
Eygelshoven 1.286
Kerkrade 666
Ashburn 657
Hong Kong 622
Ho Chi Minh City 468
Hefei 452
Frankfurt am Main 393
Hanoi 393
Fairfield 387
Southend 373
Chandler 330
San Jose 314
Santa Clara 307
Bologna 272
Seoul 209
Beijing 203
Houston 188
Woodbridge 173
Dong Ket 166
Seattle 162
Wilmington 151
Princeton 136
Ann Arbor 134
Dublin 133
Boardman 128
Milan 124
Cambridge 117
Los Angeles 112
Abidjan 109
Lauterbourg 90
Tokyo 89
Helsinki 86
New York 79
Da Nang 73
Berlin 66
Rome 58
Haiphong 57
Council Bluffs 56
Lomé 54
Bengaluru 46
Buffalo 43
Redmond 43
Munich 42
Amman 41
Hyderabad 41
Kyiv 41
Nanjing 40
Guangzhou 38
Jinan 38
Westminster 38
Chicago 37
Dallas 37
The Dalles 37
Bremen 36
São Paulo 35
Falkenstein 33
Redondo Beach 33
Turin 32
Warsaw 32
London 31
Padova 31
Amsterdam 30
Changsha 30
San Diego 30
Lappeenranta 29
Jakarta 28
Nuremberg 26
Düsseldorf 25
Florence 24
Shenyang 24
Abeokuta 23
Bangkok 23
Shanghai 23
Biên Hòa 22
Tianjin 22
Bern 21
Brooklyn 21
Brussels 21
Johannesburg 21
Modena 21
Hải Dương 20
Bến Tre 19
Vienna 19
Des Moines 18
Verona 18
Sofia 17
Dearborn 16
Orem 16
Atlanta 15
Baghdad 15
Can Tho 15
Istanbul 15
Nanchang 15
Secaucus 15
Tongling 15
Toronto 15
Yubileyny 15
Hebei 14
Saint Petersburg 14
Totale 12.771
Salva come PNG Salva come JPEG
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 2.842
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 427
CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells 295
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium 265
A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine 244
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 237
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 235
Intracranial pressure management in fulminant cerebral oedema after CAR T-cell therapy: Not all is lost! 233
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 231
Peripheral blood cellular profile at pre-lymphodepletion is associated with {CD}19-targeted {CAR}-T cell-associated neurotoxicity 223
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 223
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 222
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 216
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 215
Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy 208
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 207
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 206
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 200
Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome 200
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma 199
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 195
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity 194
CAR t-cell therapy in BOlogNa–NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON–NEUTRAL): proposed protocol and results from an Italian study 193
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 188
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study 186
Hairy Cell Leukemia: Allogeneic Transplantation Could be an Optimal Option in Selected Patients. 182
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 181
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 179
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study 177
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies 173
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients 169
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice 169
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma 169
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. 168
Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors-The MicroLinf Study 167
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 167
Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients 167
Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival 166
Different definitions in intention-to-treat analysis for chimeric antigen receptor T-cell therapy depend on research scope 165
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma 163
Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients 163
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). 162
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 159
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study 158
Management of central nervous system relapse in a young patient affected by primary mediastinal large B-cell lymphoma: A case report 158
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 154
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 154
Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. 151
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation 150
Vemurafenib mucosal side-effect. 150
Interesting activity of pegylated liposomal doxorubicin in primary refractory and multirelapsed Hodgkin lymphoma patients: Bridge to transplant 150
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience 147
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. 145
Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection 144
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 144
Correction to: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy 143
Impressive Response to Pixantrone after Allogeneic Transplant in a Multiple Relapsed Diffuse Large B-Cell Lymphoma 141
Low doses ATLG as GvHD prophylaxis in allogeneic hematopoietic stem cell transplantation for lymphomas 141
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results 140
Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice 140
Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients 139
Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. 138
Erythroderma with brentuximab vedotin (skin side effects in mycosis fungoides) 132
Erythrodermie mit Brentuximab‐Vedotin (Hautnebenwirkungen bei Mycosis fungoides) 132
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study 132
Impressive continuous complete response after mogamulizumab in a heavily pretreated Sézary syndrome patient 130
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice 129
Ultrasound-guided core needle biopsy of nodular lesions of the spleen in hematology clinical practice 129
New therapies and old side-effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia 124
Long-term efficacy and safety of ibrutinib in the treatment of CLL patients: A real life experience 124
Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series 124
Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients. 122
Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia 121
Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma 121
Clinical Response in Heavily Pretreated Mycosis Fungoides with Pembrolizumab: A Case Report 121
Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report 119
Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy 117
Prospective Validation of CAR-HEMATOTOX and a Simplified Version Predict Survival in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 CAR T-Cells: Data from CART-SIE Study 116
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma 112
A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas 111
SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy 110
The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma 108
Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors 107
Spontaneous remission of follicular lymphoma 106
Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity 106
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma 104
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 103
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma 102
Allogeneic stem cell transplantation is capable of healing a case of bone marrow aplasia following CAR-T cell therapy in a lymphoma patient 101
NR1H3 (LXRα) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma 95
Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review 92
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study 89
Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma 88
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy 88
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study 86
Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases 85
Duvelisib as bridge to allotransplantation in refractory peripheral T-cell lymphoma with T-follicular helper phenotype: case report 83
Pixantrone as bridging therapy to allogeneic transplantation or in chimeric antigen receptor T‐cell pathway in patients with diffuse large B‐cell lymphoma 81
Follicular lymphoma: the diminishing role of chemotherapy. 80
Endobronchial Presentation of Hodgkin Lymphoma Responding to Pembrolizumab: A Case Report 78
Totale 18.225
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.047
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.047
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021404 0 0 0 0 0 0 0 0 0 44 43 317
2021/20221.226 121 56 59 106 97 62 23 93 44 118 270 177
2022/20231.678 142 223 117 202 124 125 55 138 260 53 129 110
2023/2024739 56 98 67 88 64 90 37 54 24 66 39 56
2024/20253.658 169 322 299 233 432 192 291 153 113 353 263 838
2025/20269.471 691 734 604 601 724 1.694 2.087 308 1.485 543 0 0
Totale 19.223